Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata

BACKGROUND: Axitinib is an oral vascular endothelial growth factor receptor inhibitor with anti-tumour activity in renal, thyroid, and pancreatic cancer. METHODS: Axi-STS was a pathologically-stratified, non-randomised, open-label, multi-centre, phase II trial of continuous axitinib treatment in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Woll, Penella J., Gaunt, Piers, Gaskell, Charlotte, Young, Robin, Benson, Charlotte, Judson, Ian R., Seddon, Beatrice M., Marples, Maria, Ali, Nasim, Strauss, Sandra J., Lee, Alexander, Hughes, Ana, Kaur, Baljit, Hughes, David, Billingham, Lucinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628187/
https://www.ncbi.nlm.nih.gov/pubmed/37684354
http://dx.doi.org/10.1038/s41416-023-02416-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628187/
https://www.ncbi.nlm.nih.gov/pubmed/37684354
http://dx.doi.org/10.1038/s41416-023-02416-6

Ejemplares similares